37 completed, 1 terminated. 15 Phase 2, 13 Phase 3, 6 Phase 4, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Completed 14, Terminated 1 |
| Phase 3 | 13 | Completed 13 |
| Phase 4 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
Follow Menactra®: new trials by email Literature Review of Menactra® trials Research Report on Menactra®
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, Oral bivalent types 1 and 3; Poliomyelitis Vaccine (OPV) - Meningococcal Immunisation, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1528 | 2023-03-27 | 2026-01-21 |
| Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine (MenACYW Conjugate Vaccine), Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningococcal Immunisation (Healthy Volunteers) | Phase 3 | Completed | Sanofi | 360 | 2020-05-22 | 2025-09-15 |
| Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Healthy Adults, Adolescents, Children, and Toddlers in India and Healthy Adolescents and Children in the Republic of South Africa Meningococcal polysaccharide (serogroups A,C,Y and W) tetanus toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A,C,Y and W-135) diphtheria toxoid conjugate vaccine, Meningococcal polysaccharide (serogroups A, C, Y and W-135) vaccine - Meningococcal Immunization, Healthy Volunteers | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 1328 | 2019-12-30 | 2025-02-03 |
| Study of Meninigococcal Conjugate Vaccine Containing Serogroups A,C,Y,W and X (MCV5) in Healthy Adults Adjuvanted MCV-5, Non-Adjuvanted MCV-5, Menactra® - Meningococcal Vaccines | Phase 1 | Completed | PATH | 60 | 2016-08-01 | 2021-06-09 |
| Postmarketing Surveillance Study for Use of Menactra® in the Republic of Korea Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 1311 | 2016-07-21 | 2022-04-25 |
| Immune Lot Consistency, Immunogenicity, and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 3344 | 2016-07-15 | 2022-04-05 |
| Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine in Healthy Subjects in Vietnam Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 224 | 2016-06-06 | 2018-01-08 |
| Immunogenicity and Safety of a Booster Dose of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine, Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 810 | 2016-04-15 | 2022-04-05 |
| Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Completed | Sanofi Pasteur, a Sanofi Company | 100 | 2016-02-01 | 2022-04-25 | |
| Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra® Approximately 4 Years Earlier Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 110 | 2015-12-01 | 2016-11-07 |
| Immunogenicity and Safety of Two-Dose Series of Menactra® in Japanese Healthy Adult Subjects Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 60 | 2015-10-20 | 2017-11-06 |
| Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Meningococcal Diphtheria Toxoid Vaccine - Meningitis, Meningococcal Infection | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2013-06-25 | 2022-04-19 |
| Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Meningococcal polysaccharide diphtheria toxoid conjugate, Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate - Meningitis, Meningococcal Infection | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 1394 | 2012-07-01 | 2015-12-15 |
| Safety and Immunogenicity Study for Use of Menactra® Versus Adacel® in Subjects 11 to 55 Years of Age in South Korea Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®), Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed - Meningitis, Meningococcal Disease | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 300 | 2012-07-01 | 2013-12-03 |
| Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra® - Meningitis, Meningococcal Infection | Phase 2 | Completed | Sanofi Pasteur, a Sanofi Company | 834 | 2011-09-01 | 2014-11-18 |
| Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Children Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Infection | Completed | Sanofi Pasteur, a Sanofi Company | 116 | 2011-06-01 | 2016-11-11 | |
| Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®, Meningococcal Group C Conjugate vaccine: MenC - Meningitis, Meningococcal Infection | Phase 3 | Completed | Sanofi Pasteur, a Sanofi Company | 123 | 2011-05-01 | 2016-08-19 |
| Post-Marketing Safety Study of Menactra® in Healthy Children, Adolescents, and Adults in the Philippines Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Disease | Phase 4 | Completed | Sanofi Pasteur, a Sanofi Company | 538 | 2010-12-01 | 2014-11-14 |
| Antibody Persistence and Response to Re-vaccination With Either Menactra® or Menomune® 3 Years After Initial Vaccination Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide, Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate - Meningitis, Meningococcal Meningitis | Phase 2 | Completed | Sanofi | 139 | 2010-11-01 | 2012-06-25 |
| Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Vaccine GSK 134612 Versus Menactra® in Healthy Adolescents/Adults Meningococcal vaccine GSK 134612, Menactra® - Infections, Meningococcal | Phase 2 | Completed | GlaxoSmithKline | 1013 | 2010-08-19 | 2018-06-26 |
Showing 20 of 38. Sign in to see all of them.
Meningococcal Infections (30) · Meningitis (26) · Meningitis, Meningococcal (13) · Haemophilus Infections (4) · Chickenpox (3) · Diphtheria (3) · Measles (3) · Mumps (3) · Rubella (3) · Tetanus (3) · Whooping Cough (3) · Meningitis, Bacterial (1) · Poliomyelitis (1)
Sanofi Pasteur, a Sanofi Company (31) · Sanofi (4) · GlaxoSmithKline (2) · PATH (1)
United States (23) · India (4) · Puerto Rico (3) · Canada (2) · Japan (2) · Russia (2) · South Africa (2) · South Korea (2) · United Kingdom (2) · Chile (1) · Philippines (1) · Saudi Arabia (1) · Vietnam (1)
PMID 16203934, PMID 16417952, PMID 24567843, PMID 25285126, PMID 27642132, PMID 29550195, PMID 30120069, PMID 32209015, PMID 33439463
2018 (1)